Next Article in Journal
DNA Polymerases λ and β: The Double-Edged Swords of DNA Repair
Next Article in Special Issue
Towards a Better Molecular Diagnosis of FMR1-Related Disorders—A Multiyear Experience from a Reference Lab
Previous Article in Journal
Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy
Previous Article in Special Issue
Transcriptional Reactivation of the FMR1 Gene. A Possible Approach to the Treatment of the Fragile X Syndrome
Article Menu

Export Article

Open AccessArticle
Genes 2016, 7(9), 56; doi:10.3390/genes7090056

Possible Therapeutic Doses of Cannabinoid Type 1 Receptor Antagonist Reverses Key Alterations in Fragile X Syndrome Mouse Model

1
Laboratory of Neuropharmacology-NeuroPhar, Department of Experimental and Health Sciences, Program of Genetics and Neurosciences, University Pompeu Fabra, Barcelona 08003, Spain
2
Department of Neurosciences, University of the Basque Country UPV/EHU, Leioa 48940, Spain
3
Achucarro Basque Center for Neuroscience, Zamudio 48170, Spain
4
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid 28031, Spain
*
Author to whom correspondence should be addressed.
Academic Editor: Mark Hirst
Received: 21 July 2016 / Revised: 20 August 2016 / Accepted: 22 August 2016 / Published: 31 August 2016
(This article belongs to the Special Issue Fragile X Syndrome)
View Full-Text   |   Download PDF [1489 KB, uploaded 14 September 2016]   |  

Abstract

Fragile X syndrome (FXS) is the most common monogenetic cause of intellectual disability. The cognitive deficits in the mouse model for this disorder, the Fragile X Mental Retardation 1 (Fmr1) knockout (KO) mouse, have been restored by different pharmacological approaches, among those the blockade of cannabinoid type 1 (CB1) receptor. In this regard, our previous study showed that the CB1 receptor antagonist/inverse agonist rimonabant normalized a number of core features in the Fmr1 knockout mouse. Rimonabant was commercialized at high doses for its anti-obesity properties, and withdrawn from the market on the bases of mood-related adverse effects. In this study we show, by using electrophysiological approaches, that low dosages of rimonabant (0.1 mg/kg) manage to normalize metabotropic glutamate receptor dependent long-term depression (mGluR-LTD). In addition, low doses of rimonabant (from 0.01 mg/kg) equally normalized the cognitive deficit in the mouse model of FXS. These doses of rimonabant were from 30 to 300 times lower than those required to reduce body weight in rodents and to presumably produce adverse effects in humans. Furthermore, NESS0327, a CB1 receptor neutral antagonist, was also effective in preventing the novel object-recognition memory deficit in Fmr1 KO mice. These data further support targeting CB1 receptors as a relevant therapy for FXS. View Full-Text
Keywords: fragile X syndrome; synaptic plasticity; long-term depression; memory; treatment; cannabinoid receptor; CB1; endocannabinoid system fragile X syndrome; synaptic plasticity; long-term depression; memory; treatment; cannabinoid receptor; CB1; endocannabinoid system
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Gomis-González, M.; Busquets-Garcia, A.; Matute, C.; Maldonado, R.; Mato, S.; Ozaita, A. Possible Therapeutic Doses of Cannabinoid Type 1 Receptor Antagonist Reverses Key Alterations in Fragile X Syndrome Mouse Model. Genes 2016, 7, 56.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Genes EISSN 2073-4425 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top